Sareum (LON:SAR) Trading Up 11.9% – Should You Buy?

Shares of Sareum Holdings plc (LON:SAR) were up 11.9% during mid-day trading on Wednesday . The stock traded as high as GBX 15.70 and last traded at GBX 14.60. Approximately 350,549 shares traded hands during trading, a decline of 17% from the average daily volume of 421,343 shares. The stock had previously closed at GBX 13.05.

Sareum Stock Up 19.9%

The company has a market cap of £21.60 million, a price-to-earnings ratio of -4.35 and a beta of -1.08. The company has a fifty day simple moving average of GBX 14.13 and a two-hundred day simple moving average of GBX 17.71.

Sareum (LON:SAR) last released its quarterly earnings results on Thursday, October 23rd. The company reported GBX (2.40) earnings per share (EPS) for the quarter. On average, research analysts predict that Sareum Holdings plc will post -3.8 EPS for the current year.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.